Claritas HealthTech Awarded Access by NHS to Assess Value of iRAD™ Image Enhancement in Chest Images of X-Ray, MRI, CT

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

LONDON and SINGAPORE, Nov. 24, 2022 (GLOBE NEWSWIRE) — Claritas HealthTech (“Claritas”), a healthcare technology company specializing in medical image enhancement and Artificial Intelligence (AI) assisted diagnostic tools, announces today that it has been awarded access to the National Covid-19 Chest Imaging Database (NCCID) curated by the AI Lab NHSE, after a rigorous and peer-reviewed assessment process to evaluate the benefits of iRADTM across modalities and conditions.

Claritas will carry out research using iRADTM, its image enhancement Software as a Medical Device (SaMD), with leading UK-based consultant Radiologists. The study will evaluate data across modalities (X-Rays, CT, and MRI) using multiple clinical, operational, and quality parameters for the benefit of patient outcomes.

Recognising the need to evaluate the performance of new technologies with data representative of the population and by clinicians delivering that care, Claritas has designed a study to evaluate the benefits of iRADTMwith data that is representative of that population,” commented, Dr. Arup Paul, Chief Clinical Strategy Officer at Claritas.

The parameters under assessment will include the optimisation of technical image quality, improvements in clinician interpretation, lesion identification and the potential of these enhanced data sets to train more accurate AI tools to further support clinicians and improve patient safety. 

Dr. Paul added, “The evaluation of iRADTM using the NCCID could deliver benefits for patients and clinicians in multiple parts of the health ecosystem from screening programmes, A&E to complex intervention planning.” 

About Claritas HealthTech Ltd.

Claritas conducts research and development in the fields of image enhancement, machine vision and artificial intelligence (“AI”) with a focus on medical image processing and AI assisted interpretation and diagnostics. Claritas aims to transform the diagnostics industry with powerful and effective software products created using image enhancement and AI technology enabling and assisting doctors and physicians to make accurate diagnosis and improve patient lives. All Claritas are fully compliant with HIPPA, PDPA and GDPR requirements.

For more information, please visit www.claritashealthtech.com

For Media Enquiries, please contact:

Devika Dutt

d.d@claritasco.com

Staff

Recent Posts

Healthera secures £2m strategic investment to accelerate digital pharmacy platform growth and North American expansion

An additional £2 million in new funding from private investors takes the company's Series A…

33 minutes ago

Ministry of Health Kuwait Enhances Collaboration with Intalio’s Correspondence Management System

KUWAIT CITY, Kuwait, April 16, 2025 /PRNewswire/ -- In a significant step toward enhancing operational…

33 minutes ago

What if Your SOAP Notes Wrote Themselves? DentScribe.ai’s AI Captures Dental Jargon for Perfect, Real-Time Charting

SUNNYVALE, Calif., April 16, 2025 /PRNewswire/ -- Imagine finishing a dental procedure and seeing a…

33 minutes ago

The 8th China EdFest Gives Parents a Powerful Voice

SHANGHAI, April 16, 2025 /PRNewswire/ -- The 8th China Festival of Education, hosted by Wellington College…

33 minutes ago

DocNow Launches Integrated Telehealth Platform to Streamline Virtual Care for Post-Acute Providers

BELLEVUE, Wash., April 16, 2025 /PRNewswire/ -- DocNow, a leading provider of electronic health record…

33 minutes ago

LUMA Vision Receives FDA Clearance for VERAFEYE 2D/4D Cardiac Visualization Platform

Real-Time, 360-Degree Imaging Enhances Precision and Confidence in Cardiac Procedures DUBLIN, April 16, 2025 /PRNewswire/…

33 minutes ago